The fifth China International Import Expo (CIIE) is set to kick off in Shanghai from November 5th to November 10th, 2022 which is going to attract over 280 world’s top 500 companies and industry-leading enterprises.
Holding CIIE is an important decision made by China to pursue a new round of high-level opening-up, and is China’s major initiative to still widen market access to the rest of the world. CIIE held under regular epidemic prevention and control fully demonstrates the outstanding achievements of China in this regard, as well as economic and social development. Furthermore, it fully reflects China’s sincere desire to share market opportunities with the world and promote world economic recovery.
Over the past four years, more and more multinational enterprises have joined the CIIE family, seizing the opportunities as China’s willingness to open the gates of its vast domestic market.
Statistics from the Ministry of Commerce showed that exhibitors of the first four CIIEs were the reason of more than 1,500 new products, technologies and services to be launched, with a cumulative intended transaction value of over $270 billion.
More than 30 international companies including global pioneer firms participated in the fifth China International Import Expo this year in Shanghai, showing strong confidence in China’s economic growth in the future.
ZIMA attends this exhibition by presenting the following cutting-edge Hi-Tech pharmaceutical products;
- PACLINAB (#Paclitaxel Albumin-Bound)
- PALBOCAP (#Palbociclib)
- EXOPIO (#Naltrexone Extended-Release)
- PADYNEX (#Trastuzumab Emtansine)
- FOLYPRA (#Pralatrexate)
- SYPPER (#Trientine)
- PERKINRA (#Anakinra)
- BERAKSURF (#Beractant)
- PAPILLOGUARD (#HPV Vaccine)
